Phenotype
|
Fish
|
Conditions
|
Figures
|
whole organism camk2d1 expression increased amount, abnormal
|
AB + MO1-tbx5a
|
standard conditions
|
Fig. 2
from D'Aurizio et al., 2016
|
whole organism mir34a expression increased amount, abnormal
|
AB + MO1-tbx5a
|
standard conditions
|
Fig. 2
from D'Aurizio et al., 2016
|
whole organism mir30a expression increased amount, abnormal
|
AB + MO1-tbx5a
|
standard conditions
|
Fig. 2
from D'Aurizio et al., 2016
|
whole organism atp1a2a expression increased amount, abnormal
|
AB + MO1-tbx5a
|
standard conditions
|
Fig. 2
from D'Aurizio et al., 2016
|
whole organism hand2 expression increased amount, abnormal
|
AB + MO1-tbx5a
|
standard conditions
|
Fig. 2
from D'Aurizio et al., 2016
|
whole organism mef2aa expression increased amount, abnormal
|
AB + MO1-tbx5a
|
standard conditions
|
Fig. 2
from D'Aurizio et al., 2016
|
whole organism dre-mir-19a expression increased amount, abnormal
|
AB + MO1-tbx5a
|
standard conditions
|
Fig. 2
from D'Aurizio et al., 2016
|
whole organism dre-mir-7ba expression increased amount, abnormal
|
AB + MO1-tbx5a
|
standard conditions
|
Fig. 2
from D'Aurizio et al., 2016
|
whole organism robo1 expression increased amount, abnormal
|
AB + MO1-tbx5a
|
standard conditions
|
Fig. 2
from D'Aurizio et al., 2016
|
whole organism ndrg4 expression increased amount, abnormal
|
AB + MO1-tbx5a
|
standard conditions
|
Fig. 2
from D'Aurizio et al., 2016
|
whole organism mir10d expression increased amount, abnormal
|
AB + MO1-tbx5a
|
standard conditions
|
Fig. 2
from D'Aurizio et al., 2016
|
whole organism srfa expression increased amount, abnormal
|
AB + MO1-tbx5a
|
standard conditions
|
Fig. 2
from D'Aurizio et al., 2016
|
atrium myh6 expression decreased amount, abnormal
|
WT + MO1-tbx5a
|
standard conditions
|
Fig. 6
from Tsai et al., 2012
|
trunk bent, abnormal
|
WT + MO1-tbx5a
|
standard conditions
|
Fig. 1
from Tsai et al., 2012
|
whole organism badb expression amount, ameliorated
|
WT + MO1-tbx5a
|
chemical treatment by injection: growth hormone
|
Fig. 4
from Tsai et al., 2012
|
cardiac ventricle decreased contractility, abnormal
|
WT + MO1-tbx5a
|
standard conditions
|
Fig. 1
from Tsai et al., 2012
|
somite U-shaped, abnormal
|
WT + MO1-tbx5a
|
standard conditions
|
Fig. 6
from Li et al., 2014
Fig. 1
from Tsai et al., 2012
|
heart morphology, ameliorated
|
WT + MO1-tbx5a
|
chemical treatment by injection: growth hormone
|
Fig. 6
from Li et al., 2014
|
cardiac ventricle morphology, abnormal
|
WT + MO1-tbx5a
|
standard conditions
|
Fig. 4
from Ghosh et al., 2017
|
whole organism ghra expression decreased amount, abnormal
|
WT + MO1-tbx5a
|
standard conditions
|
Fig. 2
from Tsai et al., 2012
|
paired fin morphology, abnormal
|
WT + MO1-tbx5a
|
standard conditions
|
Fig. 6
from Ghosh et al., 2017
|
myocardium disorganized, abnormal
|
WT + MO1-tbx5a
|
standard conditions
|
Fig. 7
from Lu et al., 2011
|
cardiac ventricle myl7 expression amount, ameliorated
|
WT + MO1-tbx5a
|
chemical treatment by injection: growth hormone
|
Fig. 6
from Tsai et al., 2012
|
heart decreased size, abnormal
|
WT + MO1-tbx5a
|
standard conditions
|
Fig. 2
from Lu et al., 2008
|
heart malformed, abnormal
|
WT + MO1-tbx5a
|
standard conditions
|
Fig. 1
from Pi-Roig et al., 2014
Fig. 1
from Lu et al., 2011
|
cardiac ventricle myh7 expression decreased amount, abnormal
|
WT + MO1-tbx5a
|
standard conditions
|
Fig. 6
from Tsai et al., 2012
|
paired fin absent, abnormal
|
WT + MO1-tbx5a
|
standard conditions
|
Fig. 6
from Ghosh et al., 2017
|
pectoral fin morphology, abnormal
|
WT + MO1-tbx5a
|
standard conditions
|
Fig. 6
from Li et al., 2014
|
trunk decreased length, abnormal
|
WT + MO1-tbx5a
|
standard conditions
|
Fig. 1
from Lu et al., 2011
|
cardiac muscle cell bicellular tight junction dissociated from cardiac muscle cell bicellular tight junction, abnormal
|
WT + MO1-tbx5a
|
standard conditions
|
Fig. 7
from Lu et al., 2011
|
cardiac ventricle size, abnormal
|
WT + MO1-tbx5a
|
standard conditions
|
Fig. 4
from Ghosh et al., 2017
|
trunk curled, abnormal
|
WT + MO1-tbx5a
|
standard conditions
|
Fig. 1
from Lu et al., 2011
|
atrium morphology, abnormal
|
WT + MO1-tbx5a
|
standard conditions
|
Fig. 4
from Ghosh et al., 2017
|
heart morphology, abnormal
|
WT + MO1-tbx5a
|
standard conditions
|
Fig. 4
from Ghosh et al., 2017
Fig. 6
from Li et al., 2014
Fig. 1
from Tsai et al., 2012
Fig. 1,
Fig. 2,
Fig. 5
from Lu et al., 2008
Fig. 9
from Qu et al., 2008
|
whole organism cdkn1bb expression amount, ameliorated
|
WT + MO1-tbx5a
|
chemical treatment by injection: growth hormone
|
Fig. 5
from Tsai et al., 2012
|
cardiac muscle cell mitochondrion increased amount, abnormal
|
WT + MO1-tbx5a
|
standard conditions
|
Fig. 7
from Lu et al., 2011
|
pectoral fin bud absent, abnormal
|
WT + MO1-tbx5a
|
standard conditions
|
Fig. 6
from Fischer et al., 2003
|
paired fin decreased size, abnormal
|
WT + MO1-tbx5a
|
standard conditions
|
Fig. 6
from Ghosh et al., 2017
|
cardiac ventricle myl7 expression decreased amount, abnormal
|
WT + MO1-tbx5a
|
standard conditions
|
Fig. 6
from Tsai et al., 2012
|
pectoral fin upturned, abnormal
|
WT + MO1-tbx5a
|
standard conditions
|
Fig. 4
from Garrity et al., 2002
|
heart looping arrested, abnormal
|
WT + MO1-tbx5a
|
standard conditions
|
Fig. 1
from Pi-Roig et al., 2014
Fig. 4
from Garrity et al., 2002
|
whole organism cdk2 expression amount, ameliorated
|
WT + MO1-tbx5a
|
chemical treatment by injection: growth hormone
|
Fig. 5
from Tsai et al., 2012
|
whole organism bcl2a expression increased amount, abnormal
|
WT + MO1-tbx5a
|
standard conditions
|
Fig. 4
from Tsai et al., 2012
|
cardiac ventricle myh7 expression amount, ameliorated
|
WT + MO1-tbx5a
|
chemical treatment by injection: growth hormone
|
Fig. 6
from Tsai et al., 2012
|
whole organism ghrb expression decreased amount, abnormal
|
WT + MO1-tbx5a
|
standard conditions
|
Fig. 2
from Tsai et al., 2012
|
pericardium edematous, abnormal
|
WT + MO1-tbx5a
|
standard conditions
|
Fig. 4
from Ghosh et al., 2017
Fig. 6
from Ghosh et al., 2009
Fig. 1,
Fig. 2
from Lu et al., 2008
|
whole organism cdkn1bb expression increased amount, abnormal
|
WT + MO1-tbx5a
|
standard conditions
|
Fig. 5
from Tsai et al., 2012
|
somite shape, ameliorated
|
WT + MO1-tbx5a
|
chemical treatment by injection: growth hormone
|
Fig. 6
from Li et al., 2014
|
cardiac muscle cell mitochondrion swollen, abnormal
|
WT + MO1-tbx5a
|
standard conditions
|
Fig. 7
from Lu et al., 2011
|
pectoral fin aplastic, abnormal
|
WT + MO1-tbx5a
|
standard conditions
|
Fig. 5
from Pi-Roig et al., 2014
Fig. 1
from Tsai et al., 2012
Fig. 6
from Ghosh et al., 2009
|
heart development disrupted, abnormal
|
WT + MO1-tbx5a
|
standard conditions
|
Fig. 9
from Qu et al., 2008
|
heart edematous, abnormal
|
WT + MO1-tbx5a
|
standard conditions
|
Fig. 1
from Tsai et al., 2012
|
pectoral fin hypoplastic, abnormal
|
WT + MO1-tbx5a
|
standard conditions
|
Fig. 1
from Lu et al., 2011
|
pectoral fin truncated, abnormal
|
WT + MO1-tbx5a
|
standard conditions
|
Fig. 1
from Tsai et al., 2012
|
atrium size, abnormal
|
WT + MO1-tbx5a
|
standard conditions
|
Fig. 4
from Ghosh et al., 2017
|
whole organism semi-lethal (sensu genetics), abnormal
|
WT + MO1-tbx5a
|
standard conditions
|
Fig. 2
from Lu et al., 2008
|
whole organism cdk2 expression increased amount, abnormal
|
WT + MO1-tbx5a
|
standard conditions
|
Fig. 5
from Tsai et al., 2012
|
heart jogging disrupted, abnormal
|
WT + MO1-tbx5a
|
standard conditions
|
Fig. 2
from Pi-Roig et al., 2014
|
heart contraction decreased rate, abnormal
|
WT + MO1-tbx5a
|
standard conditions
|
Fig. 4
from Ghosh et al., 2017
|
whole organism lacks parts or has fewer parts of type pectoral fin, abnormal
|
WT + MO1-tbx5a
|
standard conditions
|
Fig. 4
from Garrity et al., 2002
|
whole organism badb expression increased amount, abnormal
|
WT + MO1-tbx5a
|
standard conditions
|
Fig. 4
from Tsai et al., 2012
|
heart looping disrupted, abnormal
|
WT + MO1-tbx5a
|
standard conditions
|
Fig. 1
from Pi-Roig et al., 2014
Fig. 1
from Lu et al., 2011
Fig. 6
from Ghosh et al., 2009
Fig. 1,
Fig. 2,
Fig. 5
from Lu et al., 2008
|
pectoral fin development disrupted, abnormal
|
WT + MO1-tbx5a
|
standard conditions
|
Fig. 5
from Pi-Roig et al., 2014
|
whole organism igf1 expression decreased amount, abnormal
|
WT + MO1-tbx5a
|
standard conditions
|
Fig. 2
from Tsai et al., 2012
|
apoptotic process occurrence, ameliorated
|
WT + MO1-tbx5a
|
chemical treatment by injection: growth hormone
|
Fig. 3
from Tsai et al., 2012
|
pectoral fin absent, abnormal
|
WT + MO1-tbx5a
|
standard conditions
|
Fig. 4
from Garrity et al., 2002
|
atrium myh6 expression amount, ameliorated
|
WT + MO1-tbx5a
|
chemical treatment by injection: growth hormone
|
Fig. 6
from Tsai et al., 2012
|
heart tube linear, abnormal
|
WT + MO1-tbx5a
|
standard conditions
|
Fig. 4
from Garrity et al., 2002
|
apoptotic process increased occurrence, abnormal
|
WT + MO1-tbx5a
|
standard conditions
|
Fig. 3
from Tsai et al., 2012
Fig. 1
from Lu et al., 2011
|
myocardium myofibril disorganized, abnormal
|
WT + MO1-tbx5a
|
standard conditions
|
Fig. 7
from Lu et al., 2011
|
pectoral fin morphology, ameliorated
|
WT + MO1-tbx5a
|
chemical treatment by injection: growth hormone
|
Fig. 6
from Li et al., 2014
|
heart looping process quality, abnormal
|
WT + MO1-tbx5a
|
standard conditions
|
Fig. 4
from Ghosh et al., 2017
|
whole organism akt2 expression decreased amount, abnormal
|
WT + MO1-tbx5a
|
standard conditions
|
Fig. 2
from Tsai et al., 2012
|
whole organism bcl2a expression amount, ameliorated
|
WT + MO1-tbx5a
|
chemical treatment by injection: growth hormone
|
Fig. 4
from Tsai et al., 2012
|
heart decreased size, abnormal
|
f1Tg + MO1-tbx5a
|
standard conditions
|
Fig. 4
from Tong et al., 2014
|
heart morphology, abnormal
|
twu34Tg + MO1-tbx5a
|
standard conditions
|
Fig. 6
from Guzzolino et al., 2018
Fig. 2
from Chiavacci et al., 2015
|
heart contraction rate, ameliorated
|
twu34Tg + MO1-tbx5a
|
chemical treatment by environment: sphingosine-1-phosphate receptor 1 antagonist
|
Fig. 6
from Guzzolino et al., 2018
|
pericardium edematous, abnormal
|
twu34Tg + MO1-tbx5a
|
standard conditions
|
Fig. 6
from Guzzolino et al., 2018
|
pectoral fin absent, abnormal
|
twu34Tg + MO1-tbx5a
|
chemical treatment by environment: sphingosine-1-phosphate receptor 1 antagonist
|
Fig. 6
from Guzzolino et al., 2018
|
heart development disrupted, abnormal
|
twu34Tg + MO1-tbx5a
|
standard conditions
|
Fig. 2
from Chiavacci et al., 2015
|
whole organism dead, abnormal
|
twu34Tg + MO1-tbx5a
|
standard conditions
|
Fig. 2
from Chiavacci et al., 2015
|
heart contraction decreased rate, abnormal
|
twu34Tg + MO1-tbx5a
|
control
|
Fig. 6
from Guzzolino et al., 2018
|
heart looping decreased occurrence, abnormal
|
twu34Tg + MO1-tbx5a
|
standard conditions
|
Fig. 6
from Guzzolino et al., 2018
|
pectoral fin morphology, abnormal
|
twu34Tg + MO1-tbx5a
|
standard conditions
|
Fig. 2
from Chiavacci et al., 2015
|
heart morphology, ameliorated
|
twu34Tg + MO1-tbx5a
|
chemical treatment by environment: sphingosine-1-phosphate receptor 1 antagonist
|
Fig. 6
from Guzzolino et al., 2018
|
heart straight, abnormal
|
twu34Tg + MO1-tbx5a
|
standard conditions
|
Fig. 6
from Guzzolino et al., 2018
|
pectoral fin absent, abnormal
|
twu34Tg + MO1-tbx5a
|
standard conditions
|
Fig. 6
from Guzzolino et al., 2018
|
pericardium edematous, abnormal
|
s849Tg; uto1Tg + MO1-tbx5a
|
standard conditions
|
Fig. S8
from Chiavacci et al., 2012
|
fin agenesis, abnormal
|
s849Tg; uto1Tg + MO1-tbx5a
|
standard conditions
|
Fig. S8
from Chiavacci et al., 2012
|
fin absent, abnormal
|
AB + MO1-tbx5a + MO2-tbx5b
|
standard conditions
|
Fig. 1
from Chiavacci et al., 2015
|
heart morphology, abnormal
|
AB + MO1-tbx5a + MO2-tbx5b
|
standard conditions
|
Fig. 1
from Chiavacci et al., 2015
|
fin morphology, abnormal
|
AB + MO1-tbx5a + MO2-tbx5b
|
standard conditions
|
Fig. 1
from Chiavacci et al., 2015
|
heart looping disrupted, abnormal
|
TL + MO1-tbx5a + MO3-atoh8
|
standard conditions
|
Fig. 3
from Rawnsley et al., 2013
|
heart tube shape, abnormal
|
TL + MO1-tbx5a + MO3-atoh8
|
standard conditions
|
Fig. 3
from Rawnsley et al., 2013
|
heart tube bifurcated, abnormal
|
WT + MO1-gata5 + MO1-tbx5a
|
standard conditions
|
Fig. 1
from Lou et al., 2011
|
heart morphogenesis disrupted, abnormal
|
WT + MO1-gata5 + MO1-tbx5a
|
standard conditions
|
Fig. 1
from Lou et al., 2011
|
cardiac muscle cell differentiation disrupted, abnormal
|
WT + MO1-gata5 + MO1-tbx5a
|
standard conditions
|
Fig. 1
from Lou et al., 2011
|
cardiac muscle cell decreased amount, abnormal
|
WT + MO1-gata5 + MO1-tbx5a
|
standard conditions
|
Fig. 1
from Lou et al., 2011
|
heart morphology, abnormal
|
WT + MO1-smarcd3b + MO1-tbx5a
|
standard conditions
|
Fig. 1
from Lou et al., 2011
|
heart morphogenesis disrupted, abnormal
|
WT + MO1-smarcd3b + MO1-tbx5a
|
standard conditions
|
Fig. 1
from Lou et al., 2011
|
heart jogging disrupted, abnormal
|
WT + MO1-tbx5a + MO1-tbx5b
|
standard conditions
|
Fig. 2
from Pi-Roig et al., 2014
|
heart looping disrupted, abnormal
|
WT + MO1-tbx5a + MO1-tbx5b
|
standard conditions
|
Fig. 1
from Pi-Roig et al., 2014
|
cranial nerve II decreased thickness, abnormal
|
WT + MO1-tbx5a + MO1-tbx5b
|
standard conditions
|
Fig. 4
from Pi-Roig et al., 2014
|
heart malformed, abnormal
|
WT + MO1-tbx5a + MO1-tbx5b
|
standard conditions
|
Fig. 1
from Pi-Roig et al., 2014
|
heart looping arrested, abnormal
|
WT + MO1-tbx5a + MO1-tbx5b
|
standard conditions
|
Fig. 1
from Pi-Roig et al., 2014
|
heart looping disrupted, abnormal
|
WT + MO1-tbx5a + MO5-mef2ca
|
standard conditions
|
Fig. 6,
Fig. 7
from Ghosh et al., 2009
|
pericardium edematous, abnormal
|
WT + MO1-tbx5a + MO5-mef2ca
|
standard conditions
|
Fig. 6
from Ghosh et al., 2009
|
heart morphogenesis arrested, abnormal
|
WT + MO1-gata5 + MO1-smarcd3b + MO1-tbx5a
|
standard conditions
|
Fig. 1
from Lou et al., 2011
|
cardiac muscle cell differentiation disrupted, abnormal
|
WT + MO1-gata5 + MO1-smarcd3b + MO1-tbx5a
|
standard conditions
|
Fig. 1
from Lou et al., 2011
|
heart tube bifurcated, abnormal
|
WT + MO1-gata5 + MO1-smarcd3b + MO1-tbx5a
|
standard conditions
|
Fig. 1
from Lou et al., 2011
|
cardiac muscle cell decreased amount, abnormal
|
WT + MO1-gata5 + MO1-smarcd3b + MO1-tbx5a
|
standard conditions
|
Fig. 1
from Lou et al., 2011
|
cardiac muscle cell differentiation disrupted, abnormal
|
twu34Tg + MO1-gata5 + MO1-tbx5a
|
standard conditions
|
Fig. 1
from Lou et al., 2011
|
heart bifurcated, abnormal
|
twu34Tg + MO1-gata5 + MO1-tbx5a
|
standard conditions
|
Fig. 1
from Lou et al., 2011
|
heart morphogenesis disrupted, abnormal
|
twu34Tg + MO1-gata5 + MO1-tbx5a
|
standard conditions
|
Fig. 1
from Lou et al., 2011
|
heart looping disrupted, abnormal
|
twu34Tg + MO1-smarcd3b + MO1-tbx5a
|
standard conditions
|
Fig. 1
from Lou et al., 2011
|
heart development disrupted, abnormal
|
twu34Tg + MO1-tbx5a + MO2-dre-mir-19a
|
standard conditions
|
Fig. 4
from Chiavacci et al., 2015
|
heart morphology, abnormal
|
twu34Tg + MO1-tbx5a + MO2-dre-mir-19a
|
standard conditions
|
Fig. 4
from Chiavacci et al., 2015
|
fin morphology, abnormal
|
twu34Tg + MO1-tbx5a + MO2-dre-mir-19a
|
standard conditions
|
Fig. 4
from Chiavacci et al., 2015
|
pectoral fin absent, exacerbated
|
twu34Tg + MO1-tbx5a + MO2-s1pr1
|
standard conditions
|
Fig. 6
from Guzzolino et al., 2018
|
pectoral fin amount, ameliorated
|
twu34Tg + MO1-tbx5a + MO2-s1pr1
|
standard conditions
|
Fig. 6
from Guzzolino et al., 2018
|
heart morphology, ameliorated
|
twu34Tg + MO1-tbx5a + MO2-s1pr1
|
standard conditions
|
Fig. 6
from Guzzolino et al., 2018
|
heart morphology, abnormal
|
twu34Tg + MO1-tbx5a + MO2-tbx5b
|
standard conditions
|
Fig. 1
from Chiavacci et al., 2015
|
heart morphology, abnormal
|
el133Tg + MO1-gata5 + MO1-smarcd3b + MO1-tbx5a
|
standard conditions
|
Fig. S1
from Lou et al., 2011
|
pharyngeal musculature morphology, abnormal
|
el133Tg + MO1-gata5 + MO1-smarcd3b + MO1-tbx5a
|
standard conditions
|
Fig. S1
from Lou et al., 2011
|
endocardium aplastic, abnormal
|
s843Tg + MO1-gata5 + MO1-smarcd3b + MO1-tbx5a
|
standard conditions
|
Fig. S1
from Lou et al., 2011
|
cardiac muscle cell differentiation disrupted, abnormal
|
twu34Tg + MO1-gata5 + MO1-smarcd3b + MO1-tbx5a
|
standard conditions
|
Fig. 1
from Lou et al., 2011
|
heart morphogenesis disrupted, abnormal
|
twu34Tg + MO1-gata5 + MO1-smarcd3b + MO1-tbx5a
|
standard conditions
|
Fig. 1
from Lou et al., 2011
|
heart bifurcated, abnormal
|
twu34Tg + MO1-gata5 + MO1-smarcd3b + MO1-tbx5a
|
standard conditions
|
Fig. 1
from Lou et al., 2011
|
heart morphology, abnormal
|
s957Tg; s958Tg + MO1-tbx5a
|
control
|
Fig. 4
from Wang et al., 2017
|
heart edematous, abnormal
|
s957Tg; s958Tg + MO1-tbx5a
|
control
|
Fig. 4
from Wang et al., 2017
|
heart looping arrested, abnormal
|
s957Tg; s958Tg + MO1-tbx5a
|
control
|
Fig. 4
from Wang et al., 2017
|
heart development process quality, abnormal
|
s957Tg; s958Tg + MO1-tbx5a
|
control
|
Fig. 4
from Wang et al., 2017
|